Patents by Inventor Larry E. Overman

Larry E. Overman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230057592
    Abstract: Use of H3K9me3 modulation for enhancing cognitive function and treating anxiety related disorders is presented. A composition is administered to the subject comprising a therapeutically effective amount of a SUV39H1 inhibitor comprising analogs of ETP69. The therapeutically effective amount is effective in treating cognitive dysfunction in aging and age-related disorders.
    Type: Application
    Filed: March 17, 2022
    Publication date: February 23, 2023
    Inventors: Carl W. COTMAN, Larry E. OVERMAN, Shikha SNIGDHA
  • Patent number: 11311551
    Abstract: Use of H3K9me3 modulation for enhancing cognitive function and treating anxiety related disorders is presented. A composition is administered to the subject comprising a therapeutically effective amount of a SUV39H1 inhibitor comprising analogs of ETP69. The therapeutically effective amount is effective in treating cognitive dysfunction in aging and age-related disorders.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: April 26, 2022
    Assignee: REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Carl W. Cotman, Larry E. Overman, Shikha Snigdha
  • Publication number: 20210106590
    Abstract: Use of H3K9me3 modulation for enhancing cognitive function and treating anxiety related disorders is presented. A composition is administered to the subject comprising a therapeutically effective amount of a SUV39H1 inhibitor comprising analogs of ETP69. The therapeutically effective amount is effective in treating cognitive dysfunction in aging and age-related disorders.
    Type: Application
    Filed: October 16, 2020
    Publication date: April 15, 2021
    Inventors: Carl W. COTMAN, Larry E. OVERMAN, Shikha SNIGDHA
  • Patent number: 10849910
    Abstract: Use of H3K9me3 modulation for enhancing cognitive function and treating anxiety related disorders is presented. A composition is administered to the subject comprising a therapeutically effective amount of a SUV39H1 inhibitor comprising analogs of ETP69. The therapeutically effective amount is effective in treating cognitive dysfunction in aging and age-related disorders.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: December 1, 2020
    Assignee: REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Carl W. Cotman, Larry E. Overman, Shikha Snigdha
  • Publication number: 20190209577
    Abstract: Use of H3K9me3 modulation for enhancing cognitive function and treating anxiety related disorders is presented. A composition is administered to the subject comprising a therapeutically effective amount of a SUV39H1 inhibitor comprising analogs of ETP69. The therapeutically effective amount is effective in treating cognitive dysfunction in aging and age-related disorders.
    Type: Application
    Filed: March 15, 2019
    Publication date: July 11, 2019
    Inventors: Carl W. COTMAN, Larry E. OVERMAN, Shikha SNIGDHA
  • Patent number: 10272093
    Abstract: Use of H3K9me3 modulation for enhancing cognitive function and treating anxiety related disorders is presented. A composition is administered to the subject comprising a therapeutically effective amount of a SUV39H1 inhibitor comprising analogs of ETP69. The therapeutically effective amount is effective in treating cognitive dysfunction in aging and age-related disorders.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: April 30, 2019
    Assignee: Regents of the University of California
    Inventors: Carl W. Cotman, Larry E. Overman, Shikha Snigdha
  • Publication number: 20180228808
    Abstract: Use of H3K9me3 modulation for enhancing cognitive function and treating anxiety related disorders is presented. A composition is administered to the subject comprising a therapeutically effective amount of a SUV39H1 inhibitor comprising analogs of ETP69. The therapeutically effective amount is effective in treating cognitive dysfunction in aging and age-related disorders.
    Type: Application
    Filed: June 3, 2016
    Publication date: August 16, 2018
    Inventors: Carl W. COTMAN, Larry E. OVERMAN, Shikha SNIGDHA
  • Publication number: 20030176697
    Abstract: The invention provides methods to synthesize zwitterionic pentacyclic crambescidin core intermediates having the carboxylate side chain in the natural axial orientation, and a range of crambescidin alkaloid analogs.
    Type: Application
    Filed: September 24, 2002
    Publication date: September 18, 2003
    Applicant: The Regents of the University of California
    Inventors: Larry E. Overman, Frank Stappenbeck, Andrew I McDonald, Zachary D. Aron
  • Patent number: 5627169
    Abstract: Novel phosphinic and phosphonic acid derivatives of pyridine, pyrrole and azepine with utility as antagonists of the GABA.sub.rho receptor are disclosed. These compounds have utility as modulators of the excitability of the central nervous system as mediated by their ability to specifically act on closed-channel binding sites of GABA.sub.rho receptors.
    Type: Grant
    Filed: July 20, 1994
    Date of Patent: May 6, 1997
    Assignee: The Regents of The University of California
    Inventors: Ricardo Miledi, Larry E. Overman, Yoshinori Murata, Richard M. Woodward
  • Patent number: 4675325
    Abstract: A method of making dendrobatid alkaloids with the formula ##STR1## in which A is either CH.sub.3 or H, and n is an integer from 1-9, and R is CH.sub.2 OH, CHO, ##STR2## and R.sub.1 and R.sub.2 are alkyl groups; and the use of such alkaloids to treat cardiovascular illness.
    Type: Grant
    Filed: June 21, 1984
    Date of Patent: June 23, 1987
    Assignee: The Regents of the University of California
    Inventors: Larry E. Overman, Fumitaka Ito